ILEVRO (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
ILEVRO
Date registered
Evaluation commenced
Decision date
Approval time
229 working days (255)
Active ingredients
nepafenac
Registration type
EOI
Indication
ILEVRO (eye drops) is now also indicated for the reduction in risk of postoperative macular oedema associated with cataract surgery in patients with non proliferative diabetic retinopathy.